^
Association details:
| Biomarker: | AFP elevation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
Published date:
04/06/2021
Excerpt:
...PFS was significantly longer for cabozantinib than for ramucirumab (5.5 [4.6–7.4] months versus 2.8 [2.7–4.1] months; p = 0.016)....In this MAIC, cabozantinib significantly prolonged median PFS compared with ramucirumab after prior sorafenib treatment in patients with HCC and AFP ≥ 400 ng/mL...
DOI:
10.1007/s12325-021-01700-2
Source:
Title:
Alpha Fetoprotein (AFP) Response Rate and Efficacy Results of the CELESTIAL Phase III Study of Cabozantinib (C) Tested Against Placebo (P) in Advanced Hepatocellular Carcinoma (HCC)
Published date:
09/10/2020
Excerpt:
Overall, 331 pts (70%) in the C arm and 160 (68%) in the P arm had elevated b AFP levels, and 236 (50%) and 111 (47%), respectively, were evaluable for AFP response at Week 8. Among evaluable pts, 117 pts (50%) in the C arm vs 14 (13%) in the P arm had an AFP response and 72 (31%) vs 75 (68%), respectively, had AFP progression....AFP response rate was higher with C vs P, and AFP response was associated with longer OS and PFS with C for pts with previously treated advanced HCC.
Source:
Title:
Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
Published date:
10/09/2018
Excerpt:
...median OS was 13.9 mo with C vs 10.3 mo with P (HR 0.81), and median PFS was 5.5 mo with C vs 1.9 mo with P (HR 0.47)….cabozantinib (C) improved OS and PFS vs P in patients with previously treated advanced HCC across a range of baseline AFP levels. High AFP levels were associated with a larger treatment benefit with C for both OS and PFS.
DOI:
10.1093/annonc/mdy282.085
Trial ID:
